Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA.
J Natl Cancer Inst. 2021 Jul 1;113(7):875-883. doi: 10.1093/jnci/djaa204.
Several cancer-susceptibility syndromes are reported to underlie pediatric rhabdomyosarcoma (RMS); however, to our knowledge there have been no systematic efforts to characterize the heterogeneous genetic etiologies of this often-fatal malignancy.
We performed exome-sequencing on germline DNA from 615 patients with newly diagnosed RMS consented through the Children's Oncology Group. We compared the prevalence of cancer predisposition variants in 63 autosomal-dominant cancer predisposition genes in these patients with population controls (n = 9963). All statistical tests were 2-sided.
We identified germline cancer predisposition variants in 45 RMS patients (7.3%; all FOXO1 fusion negative) across 15 autosomal dominant genes, which was statistically significantly enriched compared with controls (1.4%, P = 1.3 × 10-22). Specifically, 73.3% of the predisposition variants were found in predisposition syndrome genes previously associated with pediatric RMS risk, such as Li-Fraumeni syndrome (TP53) and neurofibromatosis type I (NF1). Notably, 5 patients had well-described oncogenic missense variants in HRAS (p.G12V and p.G12S) associated with Costello syndrome. Also, genetic etiology differed with histology, as germline variants were more frequent in embryonal vs alveolar RMS patients (10.0% vs 3.0%, P = .02). Although patients with a cancer predisposition variant tended to be younger at diagnosis (P = 9.9 × 10-4), 40.0% of germline variants were identified in those older than 3 years of age, which is in contrast to current genetic testing recommendations based on early age at diagnosis.
These findings demonstrate that genetic risk of RMS results from germline predisposition variants associated with a wide spectrum of cancer susceptibility syndromes. Germline genetic testing for children with RMS should be informed by RMS subtypes and not be limited to only young patients.
据报道,几种癌症易感性综合征是小儿横纹肌肉瘤(RMS)的基础;然而,据我们所知,尚未有系统的努力来描述这种常见致命性恶性肿瘤的异质遗传病因。
我们对通过儿童肿瘤学组同意的 615 名新诊断的 RMS 患者的生殖系 DNA 进行了外显子组测序。我们将这些患者中 63 个常染色体显性癌症易感性基因中的癌症易感性变异的发生率与人群对照(n=9963)进行了比较。所有的统计检验均为双侧检验。
我们在 15 个常染色体显性基因中发现了 45 名 RMS 患者(7.3%;均为 FOXO1 融合阴性)的生殖系癌症易感性变异,与对照组相比(1.4%,P=1.3×10-22)有统计学意义。具体而言,73.3%的易感性变异存在于先前与小儿 RMS 风险相关的易感性综合征基因中,如 Li-Fraumeni 综合征(TP53)和神经纤维瘤病 1 型(NF1)。值得注意的是,5 名患者存在与 Costello 综合征相关的 HRAS 中已描述的致癌错义变异(p.G12V 和 p.G12S)。此外,遗传病因与组织学不同,胚胎性 RMS 患者的生殖系变异更为常见(10.0% vs 3.0%,P=0.02)。尽管携带癌症易感性变异的患者在诊断时年龄较小(P=9.9×10-4),但 40.0%的生殖系变异发生在年龄大于 3 岁的患者中,这与基于早期诊断的当前遗传检测建议相反。
这些发现表明,RMS 的遗传风险源于与广泛的癌症易感性综合征相关的生殖系易感性变异。对于 RMS 患儿,应根据 RMS 亚型进行生殖系基因检测,而不限于仅对年轻患者进行检测。